Oncology
Oral Capecitabine: As Good As Fluorouracil Second Line for Metastatic Colorectal Cancer
David Cunningham
REFERENCE: Abstract 3012, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
DAVID CUNNINGHAM, Royal Marsden Hospital, London
The oral agent capeticabine is just as effective as fluorouracil for treating patients whose metastatic colorectal cancer has relapsed. This is the finding of a study in which either agent was combined with oxaliplatin. David Cunningham told Peter Goodwin about his group’s findings reported at the ECCO conference.
DAVID CUNNINGHAM, Royal Marsden Hospital, London
The oral agent capeticabine is just as effective as fluorouracil for treating patients whose metastatic colorectal cancer has relapsed. This is the finding of a study in which either agent was combined with oxaliplatin. David Cunningham told Peter Goodwin about his group’s findings reported at the ECCO conference.
Hormone Refractory Prostate Cancer: Increased Progression-Free Survival With Satraplatin and Prednisone
Cora Sternberg
REFERENCE: Abstract 4010, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
CORA STERNBERG, San Camillo and Forlanini Hospital, Rome
Satraplatin could provide a new option for patients with hormone refractory prostate cancer, by giving improved progression-free survival and time to pain progression. Anna Lacey spoke to Cora Sternberg about her group’s results from an international phase III trial, which were announced in Barcelona.
CORA STERNBERG, San Camillo and Forlanini Hospital, Rome
Satraplatin could provide a new option for patients with hormone refractory prostate cancer, by giving improved progression-free survival and time to pain progression. Anna Lacey spoke to Cora Sternberg about her group’s results from an international phase III trial, which were announced in Barcelona.
Gastrointestinal Cancers: Progress with Targeted Therapies
Robert Mayer
ROBERT MAYER, Dana-Farber Cancer Institute, Boston
One of the leading participants at the 2008 Gastrointestinal Cancers Symposium, Robert Mayer, gave Peter Goodwin his assessment of some of the emerging new therapies being announced, for colorectal, liver and pancreas cancers.
One of the leading participants at the 2008 Gastrointestinal Cancers Symposium, Robert Mayer, gave Peter Goodwin his assessment of some of the emerging new therapies being announced, for colorectal, liver and pancreas cancers.
Adjuvant Chemoradiotherapy: Big Gains In Pancreas Cancer
Charles Hsu
CHARLES HSU, Johns Hopkins University, Baltimore
Big improvements in overall survival were achieved by combining radiation with adjuvant chemotherapy for patients with pancreas cancer in a dtudy reported to the conference in Orlando. Charles Hsu told Peter Goodwin about their findings from more than 1,000 patients.
Big improvements in overall survival were achieved by combining radiation with adjuvant chemotherapy for patients with pancreas cancer in a dtudy reported to the conference in Orlando. Charles Hsu told Peter Goodwin about their findings from more than 1,000 patients.
ATAC Trial: Anastrozole Still Superior At Over Eight Years’ Follow Up
Jack Cuzick
JACK CUZICK, Wolfson Institute of Preventive Medicine, London
New data from the ATAC trial, which is testing anastrozole and tamoxifen in early breast cancer, have demonstrated the continued superiority of the aromatase inhibitor. Among other things, the data now show a benefit in the time to distant recurrence. Derek Thorne heard more from Jack Cuzick, of the Wolfson Institute of Preventive Medicine in London.
New data from the ATAC trial, which is testing anastrozole and tamoxifen in early breast cancer, have demonstrated the continued superiority of the aromatase inhibitor. Among other things, the data now show a benefit in the time to distant recurrence. Derek Thorne heard more from Jack Cuzick, of the Wolfson Institute of Preventive Medicine in London.
New Drug RAD001 Plus Letrozole In Neoadjuvant Therapy For Breast Cancer
Jose Baselga
JOSE BASELGA, Vall d’Hebron Hospital, Barcelona
RAD001, a drug targeted at the mTor pathway, has been combined with letrozole in a randomised phase II trial in breast cancer. The investigators saw more responses in the experimental arm, and so Derek Thorne got the details from Jose Baselga of Vall d’Hebron Hospital in Barcelona.
RAD001, a drug targeted at the mTor pathway, has been combined with letrozole in a randomised phase II trial in breast cancer. The investigators saw more responses in the experimental arm, and so Derek Thorne got the details from Jose Baselga of Vall d’Hebron Hospital in Barcelona.
Early Breast Cancer: Survival Benefit For Adjuvant Docetaxel/Cyclophosphamide
Stephen Jones
STEPHEN JONES, US Oncology Research, Houston
Long term data from an early breast cancer trial involving cyclophosphamide combined with docetaxel or doxorubicin have shown a survival advantage for the taxane. As Stephen Jones of US Oncology Research explained to Derek Thorne, this advantage was also seen in patients over 65.
Long term data from an early breast cancer trial involving cyclophosphamide combined with docetaxel or doxorubicin have shown a survival advantage for the taxane. As Stephen Jones of US Oncology Research explained to Derek Thorne, this advantage was also seen in patients over 65.
Live Report from ASH:
Ibritumomab Provides Benefit in Patients with Follicular Lymphoma
Anton Hagenbeek
ANTON HAGENBEEK, University Medical Centre Utrecht
For patients with advanced-stage follicular non-Hodgkin’s lymphoma, ibritumomab tiuxetan seems to prolong progression free survival by two years with favourable toxicity. Sarah Maxwell spoke to study author Anton Hagenbeek at the ASH meeting in Atlanta while George Canellos provided comment.
For patients with advanced-stage follicular non-Hodgkin’s lymphoma, ibritumomab tiuxetan seems to prolong progression free survival by two years with favourable toxicity. Sarah Maxwell spoke to study author Anton Hagenbeek at the ASH meeting in Atlanta while George Canellos provided comment.
Live Report from ASH:
Can Intensive Immunochemotherapy Cure Mantle Cell Lymphoma?
Christian Geisler
CHRISTIAN GEISLER, Rigshospitalet, Copenhagen
Mantle cell lymphoma, which was previously considered incurable, has apparently been cured in some patients on a phase II study. Derek Thorne got the details on the study – which featured an intensive immunochemotherapy approach - from Christian Geisler of Rigshospitalet in Copenhagen.
Mantle cell lymphoma, which was previously considered incurable, has apparently been cured in some patients on a phase II study. Derek Thorne got the details on the study – which featured an intensive immunochemotherapy approach - from Christian Geisler of Rigshospitalet in Copenhagen.
Live Report from ASH:
Oblimersen Extends Survival in Chronic Lymphocytic Leukemia
Susan O’Brien
SUSAN O’BRIEN, MD Anderson Cancer Center, Houston
For patients with relapsed or refractory CLL, oblimersen extends survival when added to standard fludarabine/cyclophosphamide chemotherapy. Susan O’Brien presented data from this phase III trial to the American Society of Hematology meeting in Atlanta. Sarah Maxwell reports.
For patients with relapsed or refractory CLL, oblimersen extends survival when added to standard fludarabine/cyclophosphamide chemotherapy. Susan O’Brien presented data from this phase III trial to the American Society of Hematology meeting in Atlanta. Sarah Maxwell reports.
Live Report from ASH:
Dasatinib Effective At Two Years’ Follow Up in Chronic Phase CML
Richard Stone
RICHARD STONE, Dana-Farber Cancer Institute, Boston
GEORGE CANELLOS, Dana-Farber Cancer Institute
New data shows that dasatinib is giving durable responses in patients with chronic phase chronic myeloid leukemia who have failed, or who cannot tolerate imatinib. So where does dasatinib stand as an emerging CML therapy? Richard Stone of the Dana-Farber Cancer Institute in Boston explained all to Derek Thorne, while George Canellos, of the same institute, gave another perspective on the data.
GEORGE CANELLOS, Dana-Farber Cancer Institute
New data shows that dasatinib is giving durable responses in patients with chronic phase chronic myeloid leukemia who have failed, or who cannot tolerate imatinib. So where does dasatinib stand as an emerging CML therapy? Richard Stone of the Dana-Farber Cancer Institute in Boston explained all to Derek Thorne, while George Canellos, of the same institute, gave another perspective on the data.
Live Report from ASH:
Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes
Pierre Fenaux
PIERRE FENAUX, Paris 13 University
Results from a phase III study presented at ASH suggest that the hypomethylating agent azacitidine should be the new standard of care for patients with high-risk MDS. Pierre Fenaux of Paris 13 University gave the details to Derek Thorne.
Results from a phase III study presented at ASH suggest that the hypomethylating agent azacitidine should be the new standard of care for patients with high-risk MDS. Pierre Fenaux of Paris 13 University gave the details to Derek Thorne.
Obesity, Car Travel, Climate Change: Linked?»
Phil Edwards, London School of Hyugiene and Tropical Medicine
LSHTM Audio News
Obesity Linked to Motor Transport And Climate Change
Peter Goodwin questions Phil Edwards of the London School of Hygiene and Tropical Medicine about "competition between stomachs and petrol tanks" discussed in a letter he and his colleague Ian Roberts have written to the medical magazine: The Lancet.Phil Edwards, London School of Hyugiene and Tropical Medicine
© 2008 Audio Medica - Medical Audio News Interviews & Podcasts. 
